Author Archives: admin


Older Muscle Stem Cells Rejuvenated to Function Like Younger Cells, May Help Elderly Repair Muscle

E-mail this page to a friend!

Health & Medicine for Senior Citizens

Older Muscle Stem Cells Rejuvenated to Function Like Younger Cells, May Help Elderly Repair Muscle

Stanford researchers pinpoint why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury

By Krista Conger

Feb. 17, 2014 - Researchers at the Stanford University School of Medicine have pinpointed why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury: Over time, stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew.

In the past, its been thought that muscle stem cells themselves dont change with age, and that any loss of function is primarily due to external factors in the cells environment, said Helen Blau, PhD, the Donald and Delia B. Baxter Foundation Professor.

However, when we isolated stem cells from older mice, we found that they exhibit profound changes with age. In fact, two-thirds of the cells are dysfunctional when compared to those from younger mice, and the defect persists even when transplanted into young muscles.

Blau and her colleagues also identified for the first time a process by which the older muscle stem cell populations can be rejuvenated to function like younger cells. Our findings identify a defect inherent to old muscle stem cells, she said. Most exciting is that we also discovered a way to overcome the defect. As a result, we have a new therapeutic target that could one day be used to help elderly human patients repair muscle damage.

Blau, a professor of microbiology and immunology and director of Stanfords Baxter Laboratory for Stem Cell Biology, is the senior author of a paper describing the research, published online Feb. 16 in Nature Medicine. Postdoctoral scholar Benjamin Cosgrove, PhD, and former postdoctoral scholar Penney Gilbert, PhD, now an assistant professor at the University of Toronto, are the lead authors.

Original post:
Older Muscle Stem Cells Rejuvenated to Function Like Younger Cells, May Help Elderly Repair Muscle

Scientists 'rejuventate' stem cells in elderly mice to repair muscles

PALO ALTO, Calif., Feb. 17 (UPI) -- In an experiment with mice, U.S. scientists say they've enabled muscle recovery in elderly mice by rejuvenating stem cells within their muscle tissue.

Normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury because over time stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew, researchers at Stanford University reported Sunday.

"In the past, it's been thought that muscle stem cells themselves don't change with age, and that any loss of function is primarily due to external factors in the cells' environment," Helen Blau of the university's school of medicine said.."However, when we isolated stem cells from older mice, we found that they exhibit profound changes with age. In fact, two-thirds of the cells are dysfunctional when compared to those from younger mice, and the defect persists even when transplanted into young muscles."

However, Blau and her colleagues say they've identified for the first time a process by which the older muscle stem cell populations can be rejuvenated to function like younger cells.

"Our findings identify a defect inherent to old muscle stem cells," she said. "Most exciting is that we also discovered a way to overcome the defect. As a result, we have a new therapeutic target that could one day be used to help elderly human patients repair muscle damage."

The researchers used drugs to block elevated biological activity within the stem cells that causes them to degenerate into non-stem, muscle progenitor cells.

When transplanted back into the animal, the treated, rejuvenated stem cells migrate to their natural niches and provide a long-lasting stem cell reserve to contribute to repeated demands for muscle repair, they researchers said.

"In mice, we can take cells from an old animal, treat them for seven days -- during which time their numbers expand dramatically, as much as 60-fold -- and then return them to injured muscles in old animals to facilitate their repair," Blau said.

See the original post here:
Scientists 'rejuventate' stem cells in elderly mice to repair muscles

Kerry Simon returns from first round of stem-cell trials at Mayo Clinic, plans Feb. 27 benefit

David Becker/WireImage

Doug Bell (Heraea), Eric Ripert, Anthony Bourdain, Barry Dakake (N9NE Steakhouse) and Kerry Simon (Simon) at the Palms on Saturday, Feb. 9,2013.

By Robin Leach (contact)

Monday, Feb. 17, 2014 | 6 p.m.

Iron Chef winner Kerry Simon is back home after his first week of stem-cell treatments at the Mayo Clinic. He had an emotional homecoming with his restaurant partner Elizabeth Blau and Europes leading Multiple Systems Atrophy scientist, Dr. Gregor Wenning from Austria, who had been meeting with Kerrys physician, Dr. Ryan Walsh from the downtown Cleveland Clinic Lou Ruvo Center for Brain Health.

Kerry underwent two days of stem-cell injections at the base of his spine that had been harvested from him in a December visit to Mayo in Rochester, Minn. He told me they were exhausting and painful and that his return to Las Vegas over the weekend was delayed a day while fighting a low-grade fever.

It is unknown if the treatments will benefit him in the crippling disease for which there is no cure or treatment. He will return to Minnesota in March for two months of additional stem-cell surgeries and clinical trials.

First up, though, is his celebrity chef fundraiser and rock concert at the Brain Center on Feb. 27. An after-party for the food and music stars will follow at his restaurant Simon in Palms Place. For information and tickets, please go to KeepMemoryAlive.org.

Sammy Hagar, Alice Cooper, Vince Neil and Slash are among the performers, with Oscar-nominated actor and comedian Bill Murray as MC. Jean-Georges Vongerichten, Daniel Boulud and Charlie Palmer are among the 15 guest chefs.

Meantime, the Las Vegas hospitality industry is helping Kerrys fundraiser with auction items that Christian Kohlberg will sell. They include chef dinners from Mario Batali, Thomas Keller and Todd English and celebrity chef restaurant dinners from Guy Fieri, Emeril Lagasse and Wolfgang Puck.

See the original post:
Kerry Simon returns from first round of stem-cell trials at Mayo Clinic, plans Feb. 27 benefit

Halifax students help spark interest in stem cell donation

Right now there are at least 40 Canadians hoping that, somewhere, healthy young black men with their particular genetic markers will sign up to be stem cell donors.

To me, its not something you just think about, its something you do. Its pretty simple, says 18-year-old Emmanuel John.

The Grade 12 student at Halifax West was volunteering Monday at his high school, helping register potential donors and taking swabs.

You get a couple tests and you may be a potential donor, he said. If you are, you can potentially save someones life.

The registration and swab event was put on by Canadian Blood Services OneMatch Stem Cell and Marrow Network. The network tries to match donors with people suffering from blood diseases or cancers like sickle-cell anemia and leukemia, said OneMatch co-ordinator Hailu Mulatu.

There are 750 Canadians in need of a stem cell transplant, but African-Canadians who make up just under one per cent of registered potential donors are under-represented in the national registry, said Mulatu.

Finding a donor and patient match is very difficult. And, because patients and donors must share similar genetic markers, a successful match will only be found among people of the same ethnic origin. Only about 25 per cent of donors are found in a patients family.

Ideal candidates are healthy individuals ranging in age from 17 to 35. Men are more likely to be successful donors than women, Mulatu said.

Organizers chose African Heritage Month as a good time to raise the awareness of the need for more African-Canadian donors.

By noon Monday, the majority of students turning out to the registration event were female although they appeared to be from a wide variety of cultural backgrounds.

More here:
Halifax students help spark interest in stem cell donation

Cell-signaling pathway that plays key role in age-related muscle loss identified

Washington, Feb. 17 : A new study on why skeletal muscle stem cells stop dividing and renewing muscle mass during aging points up a unique therapeutic opportunity for managing muscle-wasting conditions in humans.

According to Bradley Olwin from University of Colorado Boulder, the loss of skeletal muscle mass and function as we age can lead to sarcopenia, a debilitating muscle-wasting condition that generally hits the elderly hardest.

The new study indicates that altering two particular cell-signaling pathways independently in aged mice enhances muscle stem cell renewal and improves muscle regeneration.

One cell-signaling pathway the team identified, known as p38 MAPK, appears to be a major player in making or breaking the skeletal muscle stem cell, or satellite cell, renewal process in adult mice, Olwin said.

Hyperactivation of the p38 MAPK cell-signaling pathway inhibits the renewal of muscle stem cells in aged mice, perhaps because of cellular stress and inflammatory responses acquired during the aging process.

"We showed that the level of signaling from this cellular pathway is very important to the renewal of the satellite cells in adult mice, which was a very big surprise," Olwin said.

The results could lead to the use of low-dose inhibitors, perhaps anti-inflammatory compounds, to calm the activity in the p38 MAPK cell-signaling pathway in human muscle stem cells, the researcher said.

The study was published in the journal Nature Medicine.

--ANI (Posted on 17-02-2014)

See more here:
Cell-signaling pathway that plays key role in age-related muscle loss identified

stem cell therapy treatment for right brachial plexus by dr alok sharma, mumbai, india – Video


stem cell therapy treatment for right brachial plexus by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for right brachial plexus by dr alok sharma, mumbai, india. Stem Cell Therapy done date 21/...

By: Neurogen Brain and Spine Institute

Go here to see the original:
stem cell therapy treatment for right brachial plexus by dr alok sharma, mumbai, india - Video

Acid-bath stem-cell study under investigation

Haruko Obokata

The controversial work involved a mouse embryo injected with cells made pluripotent through stress.

A leading Japanese research institute has opened an investigation into a groundbreaking stem-cell study after concerns were raised about its credibility.

The RIKEN centre in Kobe announced on Friday that it is looking into alleged irregularities in the work of biologist Haruko Obokata, who works at the institution. She shot to fame last month as the lead author on two papers1, 2 published in Nature that demonstrated a simple way to reprogram mature mice cells into an embryonic state by simply applying stress, such as exposure to acid or physical pressure on cell membranes. The RIKEN investigation follows allegations on blog sites about the use of duplicated images in Obokatas papers, and numerous failed attempts to replicate her results.

Cells in an embryonic state can turn into the various types of cells that make up the body, and are therefore an ideal source of patient-specific cells. They can be used to study the development of disease or the effectiveness of drugs and could also be transplanted to regenerate failing organs. A consistent and straightforward path to reprogramming mature cells was first demonstrated in 2006, when a study showed that the introduction of four genes could switch the cells into an embryonic form known as induced pluripotent stem (iPS) cells3. The introduction of genes, however, introduces uncertainties about the fidelity of the cells, and Obokatas reports that the feat could be done so simply were met with awe, and a degree of scepticism (see 'Acid bath offers easy path to stem cells').

That scepticism deepened last week when blogs such as PubPeer started noting what seem to be problems in the two Nature papers and in an earlier paper from 20114, which relates to the potential of stem cells in adult tissues. In the 2011 paper, on which Obokata is first author, a figure showing bars meant to prove the presence of a certain stem-cell marker appears to have been inverted and then used to show the presence of a different stem-cell marker. A part of that same image appears in a different figure indicating yet another stem-cell marker. The paper contains another apparent unrelated duplication.

The corresponding author of that study, Charles Vacanti, an anaesthesiologist at Harvard Medical School in Boston, told Nature that he learned only last week of a mix up of some panels. He has already contacted the journal to request a correction. It certainly appears to have been an honest mistake [that] did not affect any of the data, the conclusions or any other component of the paper, says Vacanti.

The problems in the two recent Nature papers, on both of which Obokata is a corresponding author (Vacanti is a co-author on both, and corresponding author on one), also relate to images. In one paper1, one of the sections in a genomic analysis in the first figure appears to be spliced in. In the other paper2, images of two placentas meant to be from different experiments look strikingly similar.

Teruhiko Wakayama, a cloning specialist at Yamanashi University in Yamanashi prefecture, is a co-author on both of the papers and took most of the placental images. He admits that the two look similar but says it may be a case of simple confusion. Wakayama, who left RIKEN during the preparation of the manuscript, says he sent more than a hundred images to Obokata and suggests that there was confusion over which to use. He says he is now looking into the problem.

The scepticism has been inflamed by reports of difficulty in reproducing Obakatas latest results. None of ten prominent stem-cell scientists who responded to a questionnaire from Nature has had success. A blog soliciting reports from scientists in the field reports eight failures. But most of those attempts did not use the same types of cells that Obokata used.

View original post here:
Acid-bath stem-cell study under investigation

Extensive renewal of the T cell repertoire following autologous stem cell transplant in MS

PUBLIC RELEASE DATE:

17-Feb-2014

Contact: Philip Bernstein, Ph.D. ITNCommunications@immunetolerance.org 240-235-6132 Immune Tolerance Network

WA, Seattle (February 17, 2014) A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Network's (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published today in the Journal of Clinical Investigation quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly comprised of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

###

View original post here:
Extensive renewal of the T cell repertoire following autologous stem cell transplant in MS

Deep TCR Sequencing Reveals Extensive Renewal of the T Cell Repertoire Following Autologous Stem Cell Transplant in …

Contact Information

Available for logged-in reporters only

Newswise WA, Seattle (February 17, 2014) A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Networks (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published today in the Journal of Clinical Investigation (http://www.jci.org/articles/view/71691?key=b64763243f594bab6646) quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly comprised of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

About The Immune Tolerance Network The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

###

Originally posted here:
Deep TCR Sequencing Reveals Extensive Renewal of the T Cell Repertoire Following Autologous Stem Cell Transplant in ...

Rejuvenated Stem Cells Help Aging Muscles Heal

Researchers at the Stanford University School of Medicine have pinpointed why normal aging is accompanied by a diminished ability to regain strength and mobility after muscle injury: Over time, stem cells within muscle tissues dedicated to repairing damage become less able to generate new muscle fibers and struggle to self-renew.

A release from the university quotes Helen Blau PhD, the Donald and Delia B. Baxter Foundation Professor, as saying, "In the past, it's been thought that muscle stem cells themselves don't change with age, and that any loss of function is primarily due to external factors in the cells' environment. However, when we isolated stem cells from older mice, we found that they exhibit profound changes with age. In fact, two-thirds of the cells are dysfunctional when compared to those from younger mice, and the defect persists even when transplanted into young muscles."

The release explains that Blau and her colleagues also identified for the first time a process by which the older muscle stem cell populations can be rejuvenated to function like younger cells. "Our findings identify a defect inherent to old muscle stem cells," she said. "Most exciting is that we also discovered a way to overcome the defect. As a result, we have a new therapeutic target that could one day be used to help elderly human patients repair muscle damage."

Blau, a professor of microbiology and immunology and director of Stanford's Baxter Laboratory for Stem Cell Biology, is the senior author of a paper describing the research, which was published online Feberuary 16th 2014 in Nature Medicine. Postdoctoral scholar Benjamin Cosgrove, PhD, and former postdoctoral scholar Penney Gilbert, PhD, now an assistant professor at the University of Toronto, are the lead authors. The researchers found that many muscle stem cells isolated from mice that were two years old, equivalent to about 80 years of human life, exhibited elevated levels of activity in a biological cascade called the p38 MAP kinase pathway. This pathway impedes the proliferation of the stem cells and encourages them to instead become non-stem, muscle progenitor cells. As a result, although many of the old stem cells divide in a dish, the resulting colonies are very small and do not contain many stem cells. Using a drug to block this p38 MAP kinase pathway in old stem cells (while also growing them on a specialized matrix called hydrogel) allowed them to divide rapidly in the laboratory and make a large number of potent new stem cells that can robustly repair muscle damage, Blau said. "Aging is a stochastic but cumulative process," Cosgrove said. The word stochastic mean a process involving chance or probability. Cosgorce added that the team has shown that muscle stem cells progressively lose their stem cell function during aging. This treatment does not turn the clock back on dysfunctional stem cells in the aged population, he said. Rather, it stimulates stem cells from old muscle tissues that are still functional to begin dividing and self-renew."

The researchers found that, when transplanted back into the animal, the treated stem cells migrate to their natural niches and provide a long-lasting stem cell reserve to contribute to repeated demands for muscle repair. "In mice, we can take cells from an old animal, treat them for seven days during which time their numbers expand dramatically, as much as 60-fold and then return them to injured muscles in old animals to facilitate their repair," Blau said. In 2010, Blau's laboratory published a study in Science showing that muscle stem cells grown on soft hydrogel maintain their "stemness" in culture. In contrast, muscle stem cells grown on hard plastic tissue culture plates, the standard way to cultivate cells in the laboratory, quickly differentiate into more-specialized, but less therapeutically useful, muscle progenitor cells. The difference is likely due to the fact that soft hydrogel is more similar than rigid plastic to the muscle tissue environment in which the stem cells are naturally found. In the current study, the researchers found that targeting the p38 MAP kinase to induce the rapid expansion of the remaining functional stem cells from old mice required the soft hydrogel substrate. "The drug plus hydrogel boosts the small clones so that they undergo a burst of self-renewing divisions," Gilbert said. Thus, rejuvenation of the population is contingent on the synergy between biophysical and biochemical cues.

Finally, the researchers tested the ability of the rejuvenated old muscle stem cell population to repair muscle injury and restore strength in 2-year-old recipient mice. They teamed up with co-author Scott Delp, PhD, the James H. Clark Professor in the School of Engineering, who has designed a novel way to measure muscle strength in animals that had muscle injuries and then underwent the stem cell therapy. "We were able to show that transplantation of the old treated muscle stem cell population repaired the damage and restored strength to injured muscles of old mice," Cosgrove said. "Two months after transplantation, these muscles exhibited forces equivalent to young, uninjured muscles. This was the most encouraging finding of all." The researchers plan to continue their research to learn whether this technique could be used in humans. "If we could isolate the stem cells from an elderly person, expose them in culture to the proper conditions to rejuvenate them and transfer them back into a site of muscle injury, we may be able to use the person's own cells to aid recovery from trauma or to prevent localized muscle atrophy and weakness due to broken bones," Blau said. "This really opens a whole new avenue to enhance the repair of specific muscles in the elderly, especially after an injury. Our data pave the way for such a stem cell therapy."

### Other Stanford authors of the study include postdoctoral scholar Ermelinda Porpiglia, PhD; instructor Foteini Mourkioti, PhD; undergraduate student Steven Lee; senior research scientist Stephane Corbel, PhD; and medical resident Michael Llewellyn, MD, PhD. The research was supported by the National Institutes of Health (grants R25CA118681, K99AG042491, T32CA009151, K99AR061465, U01HL100397, U01HL099997, R01AG020961, R01HL096113 and R01AG009521), the California Institute for Regenerative Medicine and the Baxter Foundation.

View post:
Rejuvenated Stem Cells Help Aging Muscles Heal